Addendum
Atezolizumab (NSCLC; first line) - Addendum to Commission A21-69
Report documents
-
Addendum
Atezolizumab (NSCLC; first line) - Addendum to Commission A21-69
Dossier assessment
Indication:
First-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression in ≥ 50% of the tumour cells (TC) and who do not have EGFR mutations or ALK-positive NSCLC
Additional information
Federal Joint Committee (G-BA)
2021-11-19 A G-BA decision was published.
Project details
- Project no.
- A21-133
- Commission
- Commission awarded on 12.10.2021 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Atezolizumab (NSCLC; first line) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed